Format

Send to

Choose Destination
JAMA Netw Open. 2019 Nov 1;2(11):e1915628. doi: 10.1001/jamanetworkopen.2019.15628.

Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum Hemorrhage.

Author information

1
Department of Obstetrics, Leiden University Medical Center, Leiden, the Netherlands.
2
Jon J van Rood Center for Clinical Transfusion Research, Sanquin-Leiden University Medical Center, Leiden, the Netherlands.
3
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
4
Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
5
Department of Obstetrics and Gynecology, Deventer Hospital, Deventer, the Netherlands.
6
Athena Institute, Vrije Universiteit, Amsterdam, the Netherlands.
7
Division of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
8
Sanquin Blood Bank, Unit Transfusion Medicine, Leiden, the Netherlands.
9
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.
10
Department of Anesthesiology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
11
Department of Obstetrics, Birth Center Wilhelmina's Children Hospital, Division Woman and Baby, University Medical Centre Utrecht, Utrecht, the Netherlands.

Abstract

Importance:

Early plasma transfusion for women with severe postpartum hemorrhage (PPH) is recommended to prevent coagulopathy. However, there is no comparative, quantitative evidence on the association of early plasma transfusion with maternal outcomes.

Objective:

To compare the incidence of adverse maternal outcomes among women who received plasma during the first 60 minutes of persistent PPH vs women who did not receive plasma for similarly severe persistent PPH.

Design, Setting, and Participants:

This multicenter cohort study used a consecutive sample of women with persistent PPH, defined as PPH refractory to first-line measures to control bleeding, between January 1, 2011, and January 1, 2013. Time-dependent propensity score matching was used to select women who received plasma during the first 60 minutes of persistent PPH and match each of them with a woman who had shown the same severity and received the same treatment of PPH but who had not received plasma at the moment of matching. Transfusions were not guided by coagulation tests. Statistical analysis was performed from June 2018 to June 2019.

Exposures:

Transfusion of plasma during the first 60 minutes of persistent PPH vs no or later plasma transfusion.

Main Outcomes and Measures:

Incidence of adverse maternal outcomes, defined as a composite of death, hysterectomy, or arterial embolization.

Results:

This study included 1216 women (mean [SD] age, 31.6 [5.0] years) with persistent PPH, of whom 932 (76.6%) delivered vaginally and 780 (64.1%) had PPH caused by uterine atony. Seven women (0.6%) died because of PPH, 62 women (5.1%) had a hysterectomy, and 159 women (13.1%) had arterial embolizations. Among women who received plasma during the first 60 minutes of persistent PPH, 114 women could be matched with a comparable woman who had not received plasma at the moment of matching. The incidence of adverse maternal outcomes was similar between the women, with adverse outcomes recorded in 24 women (21.2%) who received early plasma transfusion and 23 women (19.9%) who did not receive early plasma transfusion (odds ratio, 1.09; 95% CI, 0.57-2.09). Results of sensitivity analyses were comparable to the primary results.

Conclusions and Relevance:

In this cohort study, initiation of plasma transfusion during the first 60 minutes of persistent PPH was not associated with adverse maternal outcomes compared with no or later plasma transfusion, independent of severity of PPH.

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center